Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update

Hepatology Research

Volumn 42, Issue 6, 2012, Pages 523-542

  Kaneko, Shuichi ^a,b,c   Furuse, Junji ^a,b,d   Kudo, Masatoshi ^a,b,e   Ikeda, Kenji ^a,b,f   Honda, Masao ^b,e   Nakamoto, Yasunari ^b,g   Onchi, Morikazu ^b,h   Shiota, Goshi ^b,i   Yokosuka, Osamu ^b,j   Sakaida, Isao ^b,k   Takehara, Tetsuo ^b,l   Ueno, Yoshiyuki ^b,m   Hiroishi, Kazumasa ^b,n   Nishiguchi, Shuhei ^b,o   Moriwaki, Hisataka ^b,p   Yamamoto, Kazuhide ^b,q   Sata, Michio ^b,r   Obi, Shuntaro ^b,s   Miyayama, Shiro ^b,t   Imai, Yukinori ^b,u  

^a Novel Anticancer Agent Guideline Drafting Committee ^*  (Japan)

^b Study Group on New Liver Cancer Therapies   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KINKI UNIVERSITY   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g UNIVERSITY OF FUKUI   (Japan)

^h EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ TOTTORI UNIVERSITY   (Japan)

^j CHIBA UNIVERSITY   (Japan)

^k YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o HYOGO COLLEGE OF MEDICINE   (Japan)

^p GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q OKAYAMA UNIVERSITY   (Japan)

^r KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^s Kyoundo Hospital   (Japan)

^t FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^u SAITAMA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Hepatic arterial infusion; Hepatocellular carcinoma; Miriplatin; Molecular targeting therapy; Sorafenib

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MIRIPLATIN; OCTREOTIDE; SORAFENIB; TEGAFUR;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INTERSTITIAL PNEUMONIA; JAPAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN EXFOLIATION; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 84860662043     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.00981.x     Document Type: Article

References (35)

1. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
2. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
3. Kudo M. Chapter 3 Treatment Strategy for HCC Cases Refractory for TACE (Japanese) Hepatocelluar Carcinoma Practice Manual, 2nd edn. Tokyo: Igaku-syoin, 2010; 118-21.
4. Nexavar® adverse reaction reports liver injury and interstitial pulmonary disease (Japanese). 2010. Bayer Heathcare May.
5. Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
6. Nexavar® special post marketing surveillance report for unresectable hepatocelluar carcinoma (Japanese). 2010. Bayer Heathcare September.
7. Akaza H, Okita K etal. Guideline for proper use of Nexavar® 2nd edition (Japanese). 2010. Bayer Heathcare May
8. Furuse J, Ishii H, Nakachi K etal. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-65.
9. Lencioni R, Marrero J, Venook A etal. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010; 64: 1034-41.
10. Marrero J. Sorafenib treatment and safety profile in Child-Pugh B patients characterized in first interim results of Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study 61st Annual meeting of the American Association for the Study of Liver Diseases. 2010. 1721, poster presentation.
11. Okita K. Phase III study of sorafenib in patients in Japan and South Korea with advanced hepatocellular carcinoma treated after transarterial chemoembolization. 2010. Gastrointestinal Cancers Symposium 2010.
12. Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009; 115: 4646.
13. Zhao JD, Liu J, Ren ZG etal. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol 2010; 5: 12.
14. Hsieh CH, Jeng KS, Lin CC etal. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009; 29: 65-71.
15. Abou-Alfa GK, Johnson P, Knox JJ etal. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-60.
16. Hsu CH, Shen YC, Lin ZZ etal. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010; 53: 126-31.
17. Prete SD, Montella L, Caraglia M etal. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 2010; 66: 837-44.
18. Bhojani N, Jeldres C, Patard JJ etal. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917-30.
19. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
20. Kudo M, Kubo S, Takayasu K etal. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40: 686-92.
21. Spira D, Fenchel M, Lauer UM etal. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011; 18: 89-96.
22. Horger M, Lauer UM, Schraml C etal. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9: 208.
23. Murata K, Suzuki H, Okano H etal. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2010; 36: 161-70.
24. Ueshima K, Kudo M. PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinom. Kanzo 2010; 51: 681.
25. Llovet JM. Biomarkers predicting outcome of patients with hepatocellular carcinoma: results from the randomized phase III SHARP trial Presidential Plennary Session. Hepatology 2008; 48: 372A, Abstract no. 149.
26. Zhang Z, Zhou X, Shen H etal. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009; 7: 41.
27. Shao YY, Lin ZZ, Hsu C etal. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-6.
28. Okusaka T, Kasugai H, Ishii H. A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin sitmalamer in patients with hepatocellular carcinoma ASCO Annual Meeting 2009. 2009. #4583 Poster session.
29. Okusaka T, Okada S, Nakanishi T etal. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 2004; 22: 169-76.
30. Imai N, Ikeda K, Seko Y. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosis. Kanzo 2010; 51: 758-60.
31. Hanada M, Takasu H, Kitaura M. Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis. Oncol Rep 2010; 24: 1011-8.
32. Fujiyama S, Shibata J, Maeda S etal. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer 2003; 89: 1614-9.
33. Yamashita Y, Takahashi M, Fujimura N etal. Clinical evaluation of hepatic artery embolization: comparison between Gelfoam and Lipiodol with anticancer agent. Radiat Med 1987; 5: 61-7.
34. Ikeda K, Okusaka T, Ikeda M etal. [Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate) - safety and efficacy in combination with embolizing agents]. Gan to Kagaku Ryoho 2010; 37: 271-5.
35. Maeda M, Uchida N, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity.(Japanese) Japanese Journal of. Cancer Res 1986; 77: 523-5.